PMID- 35766387 OWN - NLM STAT- MEDLINE DCOM- 20220822 LR - 20230621 IS - 1945-7197 (Electronic) IS - 0021-972X (Print) IS - 0021-972X (Linking) VI - 107 IP - 9 DP - 2022 Aug 18 TI - The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer. PG - 2511-2521 LID - 10.1210/clinem/dgac375 [doi] AB - BACKGROUND: It is unclear whether diabetes and glycemic control affects the outcomes of breast cancer, especially among those with metastatic disease. This study aims to determine the impact of diabetes and hyperglycemia on cancer progression and mortality in individuals with metastatic breast cancer (MBC). METHODS: Patients with a diagnosis of MBC between 2010 and 2021 were identified using the MBC database at 2 academic institutions. We evaluated the effects of diabetes and glycemic control on overall survival (OS) and time to next treatment (TTNT). RESULTS: We compared 244 patients with diabetes (median age 57.6 years) to 244 patients without diabetes (matched for age, sex, ethnicity, and receptor subtype). OS at 5 years [diabetes: 54% (95% CI 47-62%) vs controls: 56% (95% CI 49-63%), P = 0.65] and TTNT at 1 year [diabetes: 43% (95% CI 36-50%) vs controls: 44% (95% CI 36-51%), P = 0.33] were similar between groups. A subgroup analysis comparing those with good glycemic control and those with poor glycemic control among patients with specific receptor subtype profiles showed no differences in OS at 5 years or TTNT at 1 year. In an 8-year landmark subgroup analysis, there was worse OS among individuals with diabetes compared to controls, and OS was found to be better among those with good glycemic control compared to those with poor control. CONCLUSIONS: Diabetes was not associated with increased mortality in individuals with MBC at 5 years. However, diabetes and hyperglycemia were associated with worse OS among a cohort of longer-term survivors. These findings suggest that individualized diabetes and glycemic goals should be considered in patients with MBC. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Cheung, Yee-Ming M AU - Cheung YM AUID- ORCID: 0000-0003-3875-5698 AD - Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. AD - Department of Medicine, Endocrine Unit, Austin Hospital, University of Melbourne, Victoria, Australia. FAU - Hughes, Melissa AU - Hughes M AD - Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA. FAU - Harrod, Julia AU - Harrod J AD - Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. FAU - Files, Janet AU - Files J AD - Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA. FAU - Kirkner, Greg AU - Kirkner G AD - Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA. FAU - Buckley, Lauren AU - Buckley L AD - Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA. FAU - Lin, Nancy U AU - Lin NU AD - Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA. FAU - Tolaney, Sara M AU - Tolaney SM AD - Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA. FAU - McDonnell, Marie E AU - McDonnell ME AD - Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. FAU - Min, Le AU - Min L AUID- ORCID: 0000-0003-4363-1139 AD - Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. LA - eng GR - P50 CA168504/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism JID - 0375362 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - *Breast Neoplasms/complications/therapy MH - *Diabetes Mellitus/epidemiology MH - Female MH - Glycemic Control MH - Humans MH - *Hyperglycemia MH - Middle Aged MH - Prognosis MH - Receptor, ErbB-2 MH - Retrospective Studies PMC - PMC9761575 OTO - NOTNLM OT - cancer outcomes OT - diabetes OT - hyperglycemia OT - metastatic breast cancer OT - overall survival COIS- L.M. and M.M. received institutional research funding from Lilly. S.T. receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, Gilead, AbbVie, Athenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, and Samsung Bioepsis Inc. All other authors have no funding or conflicts of interest to disclose. EDAT- 2022/06/30 06:00 MHDA- 2022/08/23 06:00 PMCR- 2022/06/29 CRDT- 2022/06/29 08:34 PHST- 2022/03/30 00:00 [received] PHST- 2022/06/30 06:00 [pubmed] PHST- 2022/08/23 06:00 [medline] PHST- 2022/06/29 08:34 [entrez] PHST- 2022/06/29 00:00 [pmc-release] AID - 6619488 [pii] AID - dgac375 [pii] AID - 10.1210/clinem/dgac375 [doi] PST - ppublish SO - J Clin Endocrinol Metab. 2022 Aug 18;107(9):2511-2521. doi: 10.1210/clinem/dgac375.